drugset / Trial / NCT03081806

A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis Knee Pain

NCT03081806

Phase 3 Completed 399 enrolled Techfields Pharma Co. Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase 3, Multicenter, 22-Week, double-blind and 30-Week open label Study to Evaluate the Efficacy and Safety of X0002 Spray in relief of pain of subjects with Osteoarthritis of the Knee.

Timeline

Start
2021-09-24
Primary completion
2024-01-10
Completion
2024-01-10

Drugs

EvaluationDrugModalityDoseRoute
Subject IBUPROFEN TRELAMINE Small molecule

Indications